inv3st
2021-12-21
Like ty
Aquestive sheds a third after receiving FDA response for Libervant application
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693752903,"tweetId":"693752903","gmtCreate":1640086833295,"gmtModify":1640086852941,"author":{"id":3577773488711202,"idStr":"3577773488711202","authorId":3577773488711202,"authorIdStr":"3577773488711202","name":"inv3st","avatar":"https://static.tigerbbs.com/efb6f0592ef761afbf6bab2267a2e76e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":28,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like ty</p></body></html>","htmlText":"<html><head></head><body><p>Like ty</p></body></html>","text":"Like ty","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693752903","repostId":1180762572,"repostType":4,"repost":{"id":"1180762572","kind":"news","pubTimestamp":1640086307,"share":"https://www.laohu8.com/m/news/1180762572?lang=&edition=full","pubTime":"2021-12-21 19:31","market":"us","language":"en","title":"Aquestive sheds a third after receiving FDA response for Libervant application","url":"https://stock-news.laohu8.com/highlight/detail?id=1180762572","media":"seekingalpha","summary":"Aquestive Therapeutics drops nearly 30% premarket after receiving FDA notification regarding the rev","content":"<p>Aquestive Therapeutics drops nearly 30% premarket after receiving FDA notification regarding the review of the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the treatment of breakthrough seizures and seizure clusters.</p>\n<p>The notice stated, \"the Agency is still considering the regulatory issues related to the approvability of Libervant, and will not be ready to take an action by December 23, 2021. No additional information is needed from you at this time. We are currently unable to provide an estimate of the timing of an expected action; however, we will provide any updates we can as they are available.”</p>\n<p>The company is currently reaching out to the FDA to seek further clarity.</p>\n<p>In July 2021, the FDA accepted the NDA for Libervant and assigned a PDUFA target goal date of December 23, 2021.</p>\n<p>The Company continues to advance AQST-109 as it began the EPIPHAST study, with results expected in H1 2022.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive sheds a third after receiving FDA response for Libervant application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive sheds a third after receiving FDA response for Libervant application\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 19:31 GMT+8 <a href=https://seekingalpha.com/news/3782227-aquestive-sheds-a-third-after-receiving-fda-response-for-libervant-application><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aquestive Therapeutics drops nearly 30% premarket after receiving FDA notification regarding the review of the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the treatment of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3782227-aquestive-sheds-a-third-after-receiving-fda-response-for-libervant-application\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AQST":"Aquestive Therapeutics Inc."},"source_url":"https://seekingalpha.com/news/3782227-aquestive-sheds-a-third-after-receiving-fda-response-for-libervant-application","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1180762572","content_text":"Aquestive Therapeutics drops nearly 30% premarket after receiving FDA notification regarding the review of the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the treatment of breakthrough seizures and seizure clusters.\nThe notice stated, \"the Agency is still considering the regulatory issues related to the approvability of Libervant, and will not be ready to take an action by December 23, 2021. No additional information is needed from you at this time. We are currently unable to provide an estimate of the timing of an expected action; however, we will provide any updates we can as they are available.”\nThe company is currently reaching out to the FDA to seek further clarity.\nIn July 2021, the FDA accepted the NDA for Libervant and assigned a PDUFA target goal date of December 23, 2021.\nThe Company continues to advance AQST-109 as it began the EPIPHAST study, with results expected in H1 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":987,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693752903"}
精彩评论